HIGHLIGHTS
- who: Sarcoma and colleagues from the of Radiation Oncology, Duke University Medical Center, Box, Durham, NC, USA have published the research work: Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma, in the Journal: (JOURNAL) of 10/02/2012
- what: The mutational heterogeneity of patient disease is one of the main reasons clinical trials do not show the promising results predicted from laboratory tests.
SUMMARY
The authors use this model to test the response of primary mouse sarcomas to doxorubicin and to inhibition of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.